374 related articles for article (PubMed ID: 19199980)
1. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
3. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Steiner G
Cardiovasc Drugs Ther; 2009 Oct; 23(5):403-8. PubMed ID: 19757004
[TBL] [Abstract][Full Text] [Related]
4. Fibrates after the FIELD study: Some answers, more questions.
Wierzbicki AS
Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
[TBL] [Abstract][Full Text] [Related]
5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
6. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Steiner G
Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
8. Do persons with diabetes benefit from combination statin and fibrate therapy?
Rosenblit PD
Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
[TBL] [Abstract][Full Text] [Related]
9. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
10. Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.
Czupryniak L; Joshi SR; Gogtay JA; Lopez M
Expert Opin Pharmacother; 2016 Aug; 17(11):1463-73. PubMed ID: 27267786
[TBL] [Abstract][Full Text] [Related]
11. [Expediency of the use of fibrates for primary and secondary prevention of cardiovascular complications.].
Mamedov MN
Kardiologiia; 2006; 46(12):39-47. PubMed ID: 17310961
[TBL] [Abstract][Full Text] [Related]
12. Fibrates, dyslipoproteinaemia and cardiovascular disease.
Watts GF; Dimmitt SB
Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Keating GM; Croom KF
Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
[TBL] [Abstract][Full Text] [Related]
14. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Brinton EA
Curr Atheroscler Rep; 2008 Feb; 10(1):25-32. PubMed ID: 18366982
[TBL] [Abstract][Full Text] [Related]
15. More clinical lessons from the FIELD study.
Fazio S
Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
[TBL] [Abstract][Full Text] [Related]
16. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
17. Summarizing the FIELD study: lessons from a 'negative' trial.
Tsimihodimos V; Mikhailidis DP; Elisaf M
Expert Opin Pharmacother; 2013 Dec; 14(18):2601-10. PubMed ID: 24206060
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate for Diabetic Retinopathy.
Stewart S; Lois N
Asia Pac J Ophthalmol (Phila); 2018; 7(6):422-426. PubMed ID: 30058790
[TBL] [Abstract][Full Text] [Related]
19. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Keech AC; Mitchell P; Summanen PA; O'Day J; Davis TM; Moffitt MS; Taskinen MR; Simes RJ; Tse D; Williamson E; Merrifield A; Laatikainen LT; d'Emden MC; Crimet DC; O'Connell RL; Colman PG;
Lancet; 2007 Nov; 370(9600):1687-97. PubMed ID: 17988728
[TBL] [Abstract][Full Text] [Related]
20. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
